查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1585693

膀胱癌药物市场：按治疗类型、膀胱癌类型和最终用户划分 - 全球预测 2025-2030

Bladder Cancer Therapeutics Market by Treatment Type (Chemotherapy, Gene Therapy, Immunotherapy), Bladder Cancer Type (Invasive Bladder Cancer, Squamous Cell Bladder Cancer, Superficial Bladder Cancer), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年膀胱癌治疗市场价值为52.1亿美元，预计到2024年将达到55.6亿美元，复合年增长率为7.23%，到2030年将达到84.9亿美元。

膀胱癌药物市场包括多种旨在控制和治癒膀胱癌（一种癌症）的治疗方法。不同癌症阶段的治疗包括化疗、免疫治疗、放射线治疗和标靶治疗。这些治疗方法的需求源于与膀胱癌相关的高復发率和显着的患者发病率。这些治疗方法适用于医院、诊所和专门的癌症治疗中心。主要最终用户包括医疗保健提供者、患者和研究人员，每个人都在寻求能够带来更好结果的进步。一个主要驱动因素是膀胱癌盛行率不断上升，刺激了对先进治疗方法的需求。此外，意识的提高和政府促进早期诊断和早期治疗的措施也有助于市场扩张。然而，高昂的治疗成本、现有治疗的副作用以及严格的监管要求等挑战正在阻碍成长。新型疗法的研究和开发存在商机，例如个人化医疗和标靶治疗，它们有可能减少副作用并提高疗效。新兴市场也越来越多地采用先进的医疗保健解决方案，带来了利润丰厚的商机。为了抓住这些机会，产业参与者应该投资研发并与研究机构合作推动创新。加强药物分销管道和提高对新治疗方法的认识也至关重要。限制包括新药核准过程漫长，以及与现有疗法的竞争可能会延迟新疗法的推广。对于寻求发展的公司来说，扩展到生技药品、基因治疗和奈米技术是有前途的创新领域。市场竞争激烈，持续成长需要持续创新和策略联盟。了解病患需求和监管环境对于相关人员驾驭这个复杂但机会丰富的市场至关重要。

主要市场统计
基准年[2023] 52.1亿美元
预测年份 [2024] 55.6亿美元
预测年份 [2030] 84.9亿美元
复合年增长率（%） 7.23%

市场动态：揭示快速发展的膀胱癌药物市场的关键市场洞察

供需的动态交互作用正在改变膀胱癌药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 全球膀胱癌发生率上升
    • 提高对膀胱癌的认识并及时治疗
    • 加速开发针对癌症的新药
  • 市场限制因素
    • 膀胱癌治疗高成本
  • 市场机会
    • 将机器学习 (ML) 和人工智慧 (AI) 融入膀胱癌药物中
    • 持续开发膀胱癌治疗的标靶治疗和个人化医疗
  • 市场挑战
    • 执行复杂治疗的熟练医护人员有限

波特五力：开拓膀胱癌药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解膀胱癌治疗市场的外部影响

外部宏观环境因素在塑造膀胱癌治疗药物市场的绩效动态中发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解膀胱癌治疗药物市场的竞争状况

膀胱癌治疗药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵膀胱癌治疗市场供应商的绩效评估

FPNV定位矩阵是评估膀胱癌治疗市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划膀胱癌治疗市场的成功之路

膀胱癌治疗药物市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球膀胱癌发生率增加
      • 提高对膀胱癌和适当治疗的认识
      • 加大抗癌新药的开发力道
    • 抑制因素
      • 膀胱癌治疗费用高昂
    • 机会
      • 将机器学习 (ML) 和人工智慧 (AI) 融入膀胱癌药物中
      • 持续开发膀胱癌治疗的标靶治疗和个人化医疗
    • 任务
      • 缺乏能够进行复杂治疗的熟练医疗保健专业人员
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依治疗类型分類的膀胱癌治疗药物市场

  • 化疗
  • 基因治疗
  • 免疫疗法
  • 放射治疗
  • 外科手术
  • 标靶治疗

第七章依膀胱癌类型分類的膀胱癌治疗药物市场

  • 浸润性膀胱癌
  • 膀胱鳞状细胞癌
  • 表浅性膀胱癌
  • 膀胱移行细胞癌

第八章膀胱癌治疗市场：依最终用户分类

  • 门诊手术中心
  • 医院
  • 癌症专科门诊

第九章 北美和南美膀胱癌治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区膀胱癌治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲膀胱癌药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Agilent Technologies, Inc.
  • Amneal Pharmaceuticals LLC
  • AroCell AB
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Endo International PLC
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson Services, Inc.
  • Koninklijke Philips NV
  • Merck KGaA
  • Olympus Corporation
  • Pacific Edge Ltd.
  • Pfizer Inc.
  • Spectrum Pharmaceuticals, Inc.
  • UroGen Pharma Ltd.
Product Code: MRR-521BAA36EA72

The Bladder Cancer Therapeutics Market was valued at USD 5.21 billion in 2023, expected to reach USD 5.56 billion in 2024, and is projected to grow at a CAGR of 7.23%, to USD 8.49 billion by 2030.

The bladder cancer therapeutics market encompasses a range of treatments aimed at managing and potentially curing bladder cancer, a prevalent and recurrent form of cancer. It includes therapies such as chemotherapy, immunotherapy, radiation, and targeted treatments that address various cancer stages. The necessity for these therapeutics arises from the high recurrence rate and significant patient morbidity associated with bladder cancer. These therapies find application in hospitals, clinics, and specialized cancer treatment centers. Key end-users include healthcare providers, patients, and researchers, each looking for advancements that promise better outcomes. A major growth driver is the increasing prevalence of bladder cancer, spurring demand for advanced treatments. Additionally, growing awareness and government initiatives promoting early diagnosis and treatment contribute to market expansion. However, challenges such as high treatment costs, side effects of existing therapies, and stringent regulatory requirements impede growth. Opportunities lie in research and development of novel therapeutics like personalized medicine and targeted therapies, which could potentially reduce side effects and enhance efficacy. Emerging markets are also showing increased adoption of advanced healthcare solutions, presenting lucrative opportunities. To capture these opportunities, industry players should invest in R&D and collaborate with research institutions to drive innovation. Enhancing drug distribution channels and creating awareness about newer therapies is also vital. Limitations include the slow drug approval process and competition from existing therapies that may delay the uptake of new treatments. For businesses aiming at growth, venturing into biologics, gene therapies, and nanotechnology offers promising innovation areas. The market is characterized by intense competition, requiring continuous innovation and strategic partnerships for sustained growth. Understanding patient needs and regulatory landscapes will be crucial for stakeholders navigating this complex yet opportunity-rich market.

KEY MARKET STATISTICS
Base Year [2023] USD 5.21 billion
Estimated Year [2024] USD 5.56 billion
Forecast Year [2030] USD 8.49 billion
CAGR (%) 7.23%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Bladder Cancer Therapeutics Market

The Bladder Cancer Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidences of bladder cancer across the world
    • Growing awareness about bladder cancer and timely treatment
    • Increasing development of new cancer-targeting drugs
  • Market Restraints
    • High cost associated with bladder cancer treatment
  • Market Opportunities
    • Incorporation of machine learning (ML) and artificial intelligence (AI) in bladder cancer therapeutics
    • Ongoing development of targeted therapies and personalized medicine for bladder cancer treatment
  • Market Challenges
    • Limited availability of skilled healthcare professionals for administering complex treatment

Porter's Five Forces: A Strategic Tool for Navigating the Bladder Cancer Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Bladder Cancer Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Bladder Cancer Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Bladder Cancer Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Bladder Cancer Therapeutics Market

A detailed market share analysis in the Bladder Cancer Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Bladder Cancer Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Bladder Cancer Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Bladder Cancer Therapeutics Market

A strategic analysis of the Bladder Cancer Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bladder Cancer Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Agilent Technologies, Inc., Amneal Pharmaceuticals LLC, AroCell AB, Bristol-Myers Squibb Company, Eisai Co., Ltd., Eli Lilly and Company, Endo International PLC, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Johnson & Johnson Services, Inc., Koninklijke Philips N.V., Merck KGaA, Olympus Corporation, Pacific Edge Ltd., Pfizer Inc., Spectrum Pharmaceuticals, Inc., and UroGen Pharma Ltd..

Market Segmentation & Coverage

This research report categorizes the Bladder Cancer Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment Type, market is studied across Chemotherapy, Gene Therapy, Immunotherapy, Radiation therapy, Surgery, and Targeted Therapy.
  • Based on Bladder Cancer Type, market is studied across Invasive Bladder Cancer, Squamous Cell Bladder Cancer, Superficial Bladder Cancer, and Transitional Cell Bladder Cancer.
  • Based on End-User, market is studied across Ambulatory Surgical Centers, Hospitals, and Specialty Cancer Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of bladder cancer across the world
      • 5.1.1.2. Growing awareness about bladder cancer and timely treatment
      • 5.1.1.3. Increasing development of new cancer-targeting drugs
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with bladder cancer treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Incorporation of machine learning (ML) and artificial intelligence (AI) in bladder cancer therapeutics
      • 5.1.3.2. Ongoing development of targeted therapies and personalized medicine for bladder cancer treatment
    • 5.1.4. Challenges
      • 5.1.4.1. Limited availability of skilled healthcare professionals for administering complex treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Bladder Cancer Therapeutics Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Chemotherapy
  • 6.3. Gene Therapy
  • 6.4. Immunotherapy
  • 6.5. Radiation therapy
  • 6.6. Surgery
  • 6.7. Targeted Therapy

7. Bladder Cancer Therapeutics Market, by Bladder Cancer Type

  • 7.1. Introduction
  • 7.2. Invasive Bladder Cancer
  • 7.3. Squamous Cell Bladder Cancer
  • 7.4. Superficial Bladder Cancer
  • 7.5. Transitional Cell Bladder Cancer

8. Bladder Cancer Therapeutics Market, by End-User

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centers
  • 8.3. Hospitals
  • 8.4. Specialty Cancer Clinics

9. Americas Bladder Cancer Therapeutics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Bladder Cancer Therapeutics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Bladder Cancer Therapeutics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Agilent Technologies, Inc.
  • 3. Amneal Pharmaceuticals LLC
  • 4. AroCell AB
  • 5. Bristol-Myers Squibb Company
  • 6. Eisai Co., Ltd.
  • 7. Eli Lilly and Company
  • 8. Endo International PLC
  • 9. F. Hoffmann-La Roche Ltd.
  • 10. GlaxoSmithKline PLC
  • 11. Hikma Pharmaceuticals PLC
  • 12. Johnson & Johnson Services, Inc.
  • 13. Koninklijke Philips N.V.
  • 14. Merck KGaA
  • 15. Olympus Corporation
  • 16. Pacific Edge Ltd.
  • 17. Pfizer Inc.
  • 18. Spectrum Pharmaceuticals, Inc.
  • 19. UroGen Pharma Ltd.

LIST OF FIGURES

  • FIGURE 1. BLADDER CANCER THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. BLADDER CANCER THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC BLADDER CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC BLADDER CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. BLADDER CANCER THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. BLADDER CANCER THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BLADDER CANCER THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BLADDER CANCER THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY INVASIVE BLADDER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY SQUAMOUS CELL BLADDER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY SUPERFICIAL BLADDER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TRANSITIONAL CELL BLADDER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY SPECIALTY CANCER CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC BLADDER CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. AUSTRALIA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. CHINA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. INDIA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. INDONESIA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. JAPAN BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. MALAYSIA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. PHILIPPINES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. SINGAPORE BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. SOUTH KOREA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. TAIWAN BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. THAILAND BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. VIETNAM BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. DENMARK BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. EGYPT BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. FINLAND BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. FRANCE BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. GERMANY BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ISRAEL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. ITALY BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NETHERLANDS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NIGERIA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. NORWAY BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. POLAND BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. QATAR BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. RUSSIA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SAUDI ARABIA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH AFRICA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SPAIN BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SWEDEN BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. SWITZERLAND BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. TURKEY BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED ARAB EMIRATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BLADDER CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED KINGDOM BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. BLADDER CANCER THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 151. BLADDER CANCER THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023